Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – Is ICH GCP Applicable to Non-Interventional Studies?
RWE 101 - Is ICH GCP Applicable to Non-Interventional Studies? No, the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines are not applicable to non-interventional studies [...]
Real World Evidence (RWE) 101 – Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence
RWE 101 - Real World Evidence (RWE) 101 - Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence Medical AI applications hold [...]
Real World Evidence (RWE) 101 – The Declaration of Helsinki
RWE 101 - The Declaration of Helsinki The Declaration of Helsinki is a set of ethical principles that govern the conduct of medical research involving human subjects. [...]
Real World Evidence (RWE) 101 – Ethical Foundation of RWE Research
RWE 101 - Real World Evidence (RWE) 101 - Ethical Foundation of RWE Research Real-world evidence (RWE) research, which is the study of data from real-world settings, is [...]
Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research
RWE 101 - Real World Evidence (RWE) 101 - The Impact of GDPR on RWE Research The General Data Protection Regulation (GDPR) is a regulation in EU [...]
Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation
RWE 101 - Real World Evidence (RWE) 101 - De-Identification versus Pseudo-Anonymisation De-identification and pseudo-anonymization are two commonly used techniques for protecting personal information in real world [...]







